Cell and Gene Therapy Manufacturing Market is projected to reach a CAGR of nearly 9.5% between 2024 and 2032

The global cell and gene therapy manufacturing market size was worth around USD 2.11 billion in 2023 and is predicted to grow to around USD 4.77 billion by 2032, with a compound annual growth rate (CAGR) of roughly 9.5% between 2024 and 2032.

Cell and gene therapy manufacturing is the process of producing specialized treatments that use living cells or genetic material to treat or potentially cure serious diseases. The cell and gene therapy manufacturing market includes the technologies, equipment, facilities, and services needed to develop, produce, test, and deliver these advanced therapies. Unlike traditional medicines, these treatments often require highly controlled manufacturing processes because they may use a patient’s own cells or modified genetic material. Growing research into cancer, rare diseases, and inherited disorders is increasing demand for reliable manufacturing capabilities. Advances in automation, closed-system processing, and quality testing are helping manufacturers improve production efficiency and safety. Contract manufacturing companies are also supporting drug developers that lack specialized facilities. However, complex production, high costs, and strict quality requirements remain important challenges.

The cell and gene therapy manufacturing industry is growing because more therapies are entering clinical development, manufacturers need scalable production, and healthcare systems are seeking advanced treatment options for difficult-to-treat diseases.

Browse the full “Cell and Gene Therapy Manufacturing Market - By Therapy Type (Cell Therapy Manufacturing and Gene Therapy Manufacturing), By Scale (R&D and Commercial), By Workflow (Vector Production and Cell Banking), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032” Report at https://www.zionmarketresearch.com/report/cell-and-gene-therapy-manufacturing-market

Market Growth Factors

• Rising number of therapy approvals: More approved cell and gene therapies are increasing demand for reliable manufacturing capacity to produce treatments at clinical and commercial scales.
• Expansion of contract manufacturing organizations: Biotechnology companies are outsourcing production to specialized manufacturers, helping them access advanced facilities without building their own plants.
• Advances in viral vector production: New production methods are improving viral vector yields, shortening manufacturing timelines, and helping developers control production costs more effectively.

Restraints

• Extremely high production costs: Cell and gene therapy manufacturing uses complex processes, specialized equipment, and strict quality controls, keeping production expenses high.
• Limited skilled workforce: A shortage of workers with specialized cell and gene therapy manufacturing skills can slow production expansion and limit facility capacity.

Cell and Gene Therapy Manufacturing Market: Report Scope

Market Segmentation

The cell and gene therapy manufacturing market can be segmented by therapy type, manufacturing mode, scale, and end user.

Based on therapy type, the cell and gene therapy manufacturing market is classified into cell therapy and gene therapy. Cell therapy currently holds the larger share, driven by the growing number of approved CAR-T treatments for blood cancers and rising demand for advanced cancer therapies.

Based on manufacturing mode, the market is segregated into in-house manufacturing and contract manufacturing. Contract manufacturing dominates, as many companies prefer outsourcing production to specialized facilities to reduce costs and avoid building their own production sites.

Based on scale, the market is categorized into preclinical, clinical, and commercial-scale production. Clinical-scale manufacturing currently leads the market, reflecting how many therapies are still moving through trial stages before wider commercial rollout and large-scale patient use.

Based on end user, the cell and gene therapy manufacturing industry is divided into pharmaceutical and biotechnology companies and academic and research institutes. Pharmaceutical and biotechnology companies account for the largest share given their heavy investment in therapy development, clinical research, manufacturing, and commercialization.

North America dominates the global cell and gene therapy manufacturing market because of strong biotechnology research, advanced healthcare infrastructure, and high investment in innovative treatments. The United States drives regional growth with many pharmaceutical and biotechnology companies developing cell and gene therapies for cancer, rare diseases, and inherited conditions. The region also has specialized manufacturing facilities, skilled workers, and advanced technologies that support complex therapy production. Growing clinical research and the increasing number of cell and gene therapy candidates are creating steady demand for manufacturing services. Contract manufacturing organizations are expanding their capabilities to help therapy developers produce treatments without building their own expensive facilities. Government support and private investment are also funding research, manufacturing expansion, and the development of new treatments. Growing adoption of automation and closed manufacturing systems is improving production efficiency and quality control.

Key Market Players

• Lonza AG
• Thermo Fisher Scientific
• Merck KGaA
• Catalent Inc.
• Roche Diagnostics Limited
• Takara Bio Incorporation
• Boehringer Ingelheim
• Wuxi Advanced Therapeutics
• Novartis AG
• Hitachi Chemical Company Limited
• Bluebird Bio Inc.
• Cellular Therapeutics

Recent Developments

• In July 2026, Immuneel Therapeutics and THSTI announced a partnership to establish a cGMP facility for CAR-T cell therapy and lentiviral vector manufacturing, strengthening clinical-scale production capabilities in India.
• In May 2026, FUJIFILM Cellular Dynamics opened a new iPSC manufacturing facility in Madison, Wisconsin, expanding its capacity and capabilities for induced pluripotent stem cell development and manufacturing to support growing cell therapy demand.

The global Cell and Gene Therapy Manufacturing Market is segmented as follows:

By Workflow

• Vector Production
• Cell Banking

By Therapy Type

• Cell Therapy Manufacturing
• Gene Therapy Manufacturing

By Scale

• R&D
• Commercial

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com